AMENDMENTS TO THE TITLE

Replace the title with:

UTILIZATION OF VINPOCETINE TO ~~AVOID COMPLICATIONS IN PARTICULAR THOSE ASSOCIATED TO HEARING WHICH OCCUR~~ TREAT OR PREVENT HEARING LOSS ASSOCIATED WITH EPILEPSY~~, AND TREATMENT THEREOF~~

AMENDMENTS TO THE SPECIFICATION

Replace paragraph [0033] with:

[0033] The next table shows that vinpocetine inhibits the reduction in P4 wave peak amplitude induced by PTZ . In the control animals (pre-injected with vehicle) the amplitude of the P4 wave of the ABR induced by a stimulus of 100 dB at two tone frequencies (8 and 4 kHz) is progressively reduced by PTZ (left columns), whereas in the animals pre-injected with vinpocetine the reduction produced induced by PTZ in P4 amplitude is not observed (right columns). The values shown on the table are the mean ± standard errors of the P4 wave amplitudes in μV obtained from 8 animals before and at the indicated times after the injection of the convulsing agent (PTZ).

	8 kHz PTZ	8 kHz Vinpocetine & PTZ
Before	*2.88 ± 0.1*	*2.69 ± 0.1*
10 min	*2.07 ± 0.4 **	*2.56 ± 0.1*
20 min	*1.99 ± 0.3 **	*2.71 ± 0.2*
30 min	*1.92 ± 0.3 **	*2.55 ± 0.2*
50 min	*1.51 ± 0.5 **	*2.56 ± 0.1*
	4 kHz PTZ	4 kHz Vinpocetine & PTZ
Before	*3.14 ± 0.1*	*2.82 ± 0.3*
10 min	*1.70 ± 0.5 **	*2.55 ± 0.3*
20 min	*2.12 ± 0.4 **	*2.52 ± 0.2*
30 min	*1.84 ± 0.4 **	*2.55 ± 0.2*
50 min	*2.11 ± 0.3 **	*2.52 ± 0.2*

The symbol "*" indicates that a statistically significant difference was observed.

Replace paragraph [0035] with:

[0035] The next table shows that vinpocetine inhibits the hearing loss induced by the convulsing agent, PTZ. The marked increase on the auditory threshold at 4 and 8 kHz tone

frequencies induced by PTZ (left columns) is not produced in the animals pre-injected with vinpocetine before PTZ administration (right columns). The values shown on the table are the mean ± standard errors of the thresholds in dB obtained in 8 animals.

	PTZ	Vinpocetine & PTZ
8 kHz		
Before	*7.0 ± 1.2*	*6.0 ± 1.0*
30 min	*17 ± 2.0 **	*6.0 ± 1.0*
50 min	*21 ± 2.4 **	*6.0 ± 1.0*
4 kHz		
Before	*21 ± 1.0*	*20 ± 1.6*
30 min	*28 ± 2.0 **	*18 ± 1.2*
50 min	*29 ± 1.0 **	*18 ± 1.2*

The symbol "*" indicates that a statistically significant difference was observed.

Replace paragraph [0041] with:

[0041] The following table shows that the increased latency of the P4 wave of the ABR induced by the stimulus of 100 dB at 4 and 8 kHz tone frequencies observed at the indicated times after the injection of 4-AP in control animals (left columns), is lost when 4-AP is injected in the vinpocetine pre-treated animals (right columns).

	8 kHz 4-AP	8 kHz Vinpocetine & 4-AP
Before	*3.48 ± 0.06*	*3.48 ± 0.04*
30 min	*3.51 ± 0.13*	*3.55 ± 0.07*
60 min	*3.80 ± 0.10 **	*3.45 ± 0.08*
80 min	*3.80 ± 0.10 **	*3.36 ± 0.05*
100 min	*3.83 ± 0.12 **	*3.35 ± 0.07*
	4 kHz 4-AP	4 kHz Vinpocetine & 4-AP
Before	*3.50 ± 0.02*	*3.45 ± 0.06*
30 min	*3.78 ± 0.09 **	*3.37 ± 0.06*
60 min	*3.78 ± 0.09 **	*3.54 ± 0.11*
80 min	*3.78 ± 0.09**	*3.56 ± 0.04*
100 min	*3.75 ± 0.10**	*3.43 ± 0.09*

The symbol "*" indicates that a statistically significant difference was observed.

Replace paragraph [0041] with:

[0042] Vinpocetine inhibits the hearing loss induced by 4-AP. The following table shows that the increase on the auditory threshold induced by 4-AP at 8 and 4 kHz tone frequencies in control animals (left columns) is lost in the vinpocetine treated animals (right columns).

	4-AP	Vinpocetine & 4-AP
8 kHz		
Before	*3.8 ± 1.3*	*2.5 ± 1.4*
30 min	*10.0 ± 2.0 **	*-1.3 ± 2.4*
60 min	*23.8 ± 6.3 **	*0.0 ± 3.5*
4 kHz		
Before	*13.8 ± 1.3*	*13.8 ± 1.3*
30 min	*20 ± 2.0 **	*11.3 ± 1.3*
60 min	*30 ± 3.5 **	*11.3 ± 1.3*

The symbol "*" indicates that a statistically significant difference was observed.